Lilly's Blowout Quarter Masking Price Erosion: Rally May Be Overextended

What happened

Eli Lilly reported a blowout Q3 2026 with Mounjaro revenue up 65% and Zepbound up 49%, driving total revenue 39% higher and prompting a full-year guidance raise to $91-92 billion. However, realized prices fell 15% in the quarter and 14% year-to-date, while sales rebates and discounts ballooned to $24.17 billion from $17.38 billion, signaling that access expansion is becoming costlier. The quarter also included one-time revenue boosts that are unlikely to repeat, adding uncertainty to the sustainability of growth. The stock trades at 45.9x earnings after a 6% post-earnings jump, leaving no margin of safety with base case intrinsic value near $1,380 versus the current price around $1,374. Investors must closely monitor whether tirzepatide volume growth can continue to outrun gross-to-net pressure and whether retatrutide meets its Q1 2027 submission timeline.

Implication

Monitor upcoming quarters for evidence that tirzepatide volume growth remains sufficient to offset declining net pricing and rising rebates; confirm retatrutide submission and meaningful Foundayo contribution before adding. Valuation leaves little room for disappointment; bear case downside to $1,150 if payer pressure intensifies.

Thesis delta

The blowout quarter confirms strong demand but does not change the WAIT rating due to worsening gross-to-net dynamics and a rich valuation. One-time boosts and persistent price erosion raise the bar for future quarters. The investment thesis remains unchanged: wait for proof of volume-led growth and pipeline execution.